Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Company Overview
Schrodinger, Inc. stands as a unique enterprise where advanced molecular simulation technology meets impactful enterprise software solutions. The company is deeply rooted in transforming drug discovery and materials science research through innovative software and strategic research collaborations. Its dual operating segments—Software and Drug Discovery—serve a broad spectrum of customers in pharmaceuticals, biotechnology, and materials science industries, enhancing research precision and accelerating development timelines.
Core Business Areas
The company is organized into two fundamental segments:
- Software Segment: This unit is dedicated to providing state-of-the-art molecular simulation software that aids scientists in optimizing research processes. By leveraging its predictive capabilities through advanced computational models, Schrodinger helps customers reduce research costs and streamline drug discovery pipelines.
- Drug Discovery Segment: Focused on generating revenue from a diverse portfolio of preclinical and clinical programs, this segment operates through internally managed initiatives as well as strategic collaborations. It harnesses scientific insights and milestone-based research funding to push forward breakthroughs in therapeutic development and materials advancements.
Market Significance
Schrodinger’s innovative approach is built on the foundation of scientific research excellence and advanced technological application. The integration of cutting-edge molecular simulations within its software solutions offers a competitive advantage to researchers, supporting faster and more accurate decision-making processes. In an industry driven by complex R&D challenges, the company’s unique dual model positions it as an instrumental contributor to the progression of life sciences and materials research.
Scientific Impact and Expertise
Underpinning its commercial success is a robust commitment to science. Schrodinger’s significant investments in basic research have resulted in numerous scientific breakthroughs, which are frequently validated through peer-reviewed publications. This dedication to foundational research and evidence-based innovation not only reinforces the company's market credibility but also provides a roadmap for future scientific endeavors in drug discovery and beyond.
Collaborations and Strategic Partnerships
Collaboration stands at the heart of Schrodinger’s operational ethos. The company has established deep, long-term partnerships across various industries, including pharmaceuticals, biotechnology, chemicals, and electronics. By collaborating with key industry players and even contributing to ventures like biotechnology startups, Schrodinger extends its innovative reach and fosters a dynamic exchange of scientific expertise.
Competitive Landscape
In a competitive market characterized by rapid advancements in computational chemistry and software-driven research, Schrodinger differentiates itself through its integrated business model. By combining software-driven research tools with active participation in drug discovery programs, the company offers a comprehensive approach that addresses both immediate research needs and the broader, long-term challenges of drug development. Its focus on quality, scientific rigor, and technological innovation ensures that its solutions remain indispensable in an increasingly complex market environment.
Overall, Schrodinger, Inc. epitomizes a blend of scientific excellence and technological expertise that drives innovation across critical sectors. Its contributions to advanced molecular simulations, combined with a clear value proposition in transforming drug discovery and materials science research, make it a pivotal player in the evolution of modern research and development.
Schrödinger (SDGR) announced upcoming presentations of preclinical data for two investigational cancer treatments at the AACR Annual Meeting 2025 in Chicago. The company will present data on SGR-3515, a Wee1/Myt1 inhibitor, showing improved therapeutic results through optimized intermittent dosing in preclinical oncology models. A Phase 1 clinical trial for SGR-3515 is ongoing, with initial data expected in H2 2025.
Additionally, SDGR will present findings on a machine learning model that predicts drug combination responses with Wee1 inhibitors. The company will also showcase the first preclinical data for SGR-4174, their SOS1 inhibitor targeting KRAS-driven cancers. The data suggests SGR-4174 has a differentiated profile supporting its development for KRAS mutant cancers and rare diseases arising from KRAS pathway mutations.
Schrödinger (SDGR) has announced new inducement grants for recently hired employees. The company granted a non-statutory stock option to purchase 1,575 shares to one employee and restricted stock units (RSUs) for 6,943 shares to seven employees.
The stock option, priced at $22.90 per share, has a ten-year term and vests over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months. The RSUs also vest over four years, with 25% vesting after the first year and the remaining portions vesting annually over three years.
These grants were made under the company's 2021 Inducement Equity Incentive Plan and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (Nasdaq: SDGR) has appointed Bridget van Kralingen to its Board of Directors, effective March 7, 2025. Van Kralingen brings over 35 years of experience in global technology and software business leadership. She currently serves as a senior partner at Motive Partners, an investment firm focused on technology-enabled companies.
Prior to her current role, van Kralingen spent nearly 18 years at IBM, most recently as chief executive/senior vice president of IBM Global Markets, where she managed $80 billion in revenue and profit. She previously led IBM's Industry Platforms software division and served as a managing partner at Deloitte Consulting for 15 years.
Van Kralingen currently holds board positions at Teradyne, IEX Group, Travelers Companies, and Discovery
Schrödinger (SDGR) reported strong Q4 and full-year 2024 results, with total software revenue reaching $180.4 million, up 13.3% from 2023. Q4 total revenue increased 19.1% to $88.3 million.
The company's software business showed resilience with total annual contract value increasing 23.7% to $190.8 million. However, full-year drug discovery revenue decreased to $27.2 million from $57.5 million in 2023. The company reported a net loss of $187.1 million for 2024.
Looking ahead to 2025, Schrödinger expects:
- Software revenue growth of 10-15%
- Drug discovery revenue of $45-50 million
- Software gross margin of 74-75%
- Operating expense growth less than 5%
The company expanded collaborations with Eli Lilly and Otsuka, and received a $150 million upfront payment from Novartis in January 2025. Initial Phase 1 data from three proprietary programs is expected in 2025.
Schrödinger (SDGR) has announced its management's participation in three major investor conferences in March 2025. The company will be featured in fireside chat sessions at the following events:
• TD Cowen 45th Annual Health Care Conference on March 4 at 10:30 a.m. ET
• Leerink Partners Global Biopharma Conference on March 10 at 3:40 p.m. ET
• KBCM Healthcare Forum on March 18 at 9:00 a.m. ET
All discussions will be accessible through the Investors section of Schrödinger's website and will remain available for approximately 90 days after each event.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 5,445 shares of common stock to five newly hired employees on February 17, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.
Schrödinger (Nasdaq: SDGR) has announced it will release its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors can access the live webcast through the company's website's 'Investors' section, where it will remain available for approximately 90 days.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 4,840 shares of common stock to four newly hired employees on January 20, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.
Schrödinger provided an update on its 2024 progress and outlined its 2025 strategic priorities. Key highlights include:
Expanded Collaborations: Schrödinger expanded its research collaboration with Otsuka Pharmaceutical Co., , and its agreement with Novartis, which includes a $150 million upfront payment expected in Q1 2025.
2024 Achievements: The company launched initiatives to enhance its computational platform and introduced LiveDesign Biologics. It published 29 peer-reviewed articles and advanced Phase 1 clinical studies for SGR-1505, SGR-2921, and SGR-3515. The FDA granted Fast Track Designation to SGR-2921.
Collaborations and Investments: Schrödinger announced a $150 million collaboration with Novartis, with potential milestone payments of up to $2.3 billion. Co-founded companies, including Morphic Holding and Ajax Therapeutics, made significant progress in their respective fields.
2025 Strategic Priorities: Schrödinger aims to increase customer adoption of its technology, advance predictive toxicology, and present initial Phase 1 data for SGR-1505, SGR-2921, and SGR-3515.
Schrödinger will release its Q4 and full-year financial results on February 26, 2025.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 8,365 shares to six newly hired employees on December 12, 2024. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee. The RSUs will vest over four years, with 25% vesting after 12 months of continuous service, followed by equal yearly installments of 25% over the next three years. These grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
What is Schrodinger, Inc.'s core business model?
How does Schrodinger generate revenue?
Which industries benefit from Schrodinger's solutions?
What distinguishes Schrodinger's simulation software?
What role do collaborations play in Schrodinger's business?
How is scientific expertise reflected in the company's operations?
How does Schrodinger compare to competitors in its field?
